Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

NCT02141542 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: Tremelimumab
DRUG: MEDI3617

Sponsor

F. Stephen Hodi, MD

Collaborators

[object Object]